Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma.
about
Consolidation biochemotherapy for patients with advanced nonsmall cell lung carcinoma responding to induction PVM (cisplatin, vinblastine, mitomycin-C) regimen. A phase II study.Metastasectomy for recurrent stage IV melanoma.Adjuvant therapy in melanoma.Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysisSouthwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia GroupMetastatic melanoma: chemotherapy to biochemotherapy.Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial cLong-term survival in patients with metastatic melanoma treated with DTIC or temozolomide.Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study.Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)Low back pain as the presenting sign in a patient with primary extradural melanoma of the thoracic spine--a metastatic disease 17 years after complete surgical resectionHigh-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic melanoma.
P2860
Q33495758-D0BBF06A-412D-430C-9681-10882AED1000Q33707209-9048C45C-E583-4390-8C52-827C250EE935Q34067633-D5505906-100F-4827-A0E5-629C517BE2AFQ34170003-9F417E52-2CFE-4C7C-A73E-443D71164CC8Q34484199-2363019B-B156-4E37-809C-4BFCAF97829DQ34573040-3C9419C6-1AAD-465E-A21D-E77938AED2F2Q34600089-ED992822-A0AB-4CFD-857F-6F19E2CA4604Q35584186-C748551F-CEB5-451C-A123-AFC98B15CB31Q36115587-541C4682-B1F6-4317-A4A9-477B1A55A8D7Q36422749-2EE7E7DA-F7C4-4733-8DC1-CD318D491FDFQ36643649-7BDD44C4-4F80-4398-ACBF-19D6C2B8B3C9Q39583611-7097EC88-432A-469C-85E2-59CAE61123CFQ43707361-1110E89C-9711-4B80-A231-11EBFC644CE3
P2860
Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma.
description
1994 nî lūn-bûn
@nan
1994 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Multiinstitutional phase II tr ...... erapy for metastatic melanoma.
@ast
Multiinstitutional phase II tr ...... erapy for metastatic melanoma.
@en
type
label
Multiinstitutional phase II tr ...... erapy for metastatic melanoma.
@ast
Multiinstitutional phase II tr ...... erapy for metastatic melanoma.
@en
prefLabel
Multiinstitutional phase II tr ...... erapy for metastatic melanoma.
@ast
Multiinstitutional phase II tr ...... erapy for metastatic melanoma.
@en
P2093
P1476
Multiinstitutional phase II tr ...... erapy for metastatic melanoma.
@en
P2093
J A Sosman
J A Sparano
K A Margolin
K R O'Boyle
M B Atkins
M L Ernest
R I Fisher
P304
P356
10.1200/JCO.1994.12.8.1553
P407
P577
1994-08-01T00:00:00Z